Home › Multiple Myeloma › Louisiana
Pag-aaral pangklinika para sa Multiple Myeloma sa Louisiana
10 pag-aaral para sa Multiple Myeloma ang naghahanap ng mga kalahok sa mga site sa Louisiana.
Mga Lungsod sa Louisiana
Opisyal na teksto ng pag-aaral (English)
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- East Jefferson General Hospital /ID# 251204, Metairie
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 10, 2026 · NCT05650632Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
- LSU Health Baton Rouge-North Clinic, Baton Rouge
- Our Lady of the Lake Physician Group, Baton Rouge
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT06948084A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- LSUHSC Shreveport Feist-Weiller Cancer Center, Shreveport
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT05552222A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Local Institution - 0385, Shreveport
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 30, 2026 · NCT05519085A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Louisiana State University Health Sciences Shreveport, Shreveport
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 29, 2026 · NCT06615479Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
- Mary Bird Perkins Cancer Center, Baton Rouge
Nagre-recruitPhase 4
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 27, 2026 · NCT07609940A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- LSU Health Feist Weiller Cancer Center, Shreveport
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07518186A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Pontchartrain Cancer Center, Covington
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT07477587A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- GSK Investigational Site, Baton Rouge
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT07227311Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Baton Rouge
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 14, 2026 · NCT07764978Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.